Bristol-Backed Program May Spur Immunotherapy Use In Community Setting
This article was originally published in The Pink Sheet Daily
With Yervoy/Opdivo melanoma combo and Keytruda lung cancer approvals right around the corner, a new educational program from the Association of Community Cancer Centers aims to encourage immunotherapy adoption outside of academic centers.
You may also be interested in...
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.